Mirus Bio receives ISO 13485:2016 certification, underscoring the quality of processes used to support GMP product portfolio. Read more

TransIT-LT1 Transfection Reagent – 5 X 1.0 mL

SKU MIR 2305 Categories , Tag



  • Broad Spectrum DNA Delivery – Utilize one transfection reagent and protocol for a variety of cells
  • Low Cellular Toxicity – Maintain cell density and reduce experimental biases  Learn more >>
  • High Efficiency Delivery – Achieve expression in a large population of cells for experimental success
  • Deliver Single or Multiple Plasmids – Suitable for applications such as virus production


SKU: MIR 2305

Supporting Data



TransIT-LT1 Transfection Reagent iPS Cells Data

Exceptional Transfection Efficiency in Human Induced Pluripotent Stem Cells (iPSCs) via Reverse Transfection with TransIT®-LT1. The TransIT®-LT1 Transfection Reagent was used to reverse transfect 1.3 x 106 iPS cells with a ZsGreen expressing plasmid (Clontech). Reverse transfections were performed in 6-well plates using 12 µl of TransIT®-LT1 Transfection Reagent to deliver 4 µg of DNA (3:1, reagent: DNA). Cells were visualized 48 hours post-transfection and imaged under a 10X objective with an Olympus IX71® Inverted Microscope. Images are (A) phase contrast and (B) green fluorescence. Cells were assayed 48 hours post-transfection on an Accuri® Cytometer. The histogram (C) shows untransfected cells (black line) compared to cells transfected with plasmid using TransIT®-LT1 (green line). See more information on stem cell applications.

TransIT-LT1 high efficiency transfection iCell Cardiomyocytes Fujifilm CDI data

High Efficiency Transfection of iCell® Cardiomyocytes Using TransIT®-LT1 Transfection Reagent. iCell® Cardiomyocytes were plated at 20,000 cells/well in a 96 well tissue culture plate coated with 0.1% gelatin. After allowing the cells to recover from thaw, cells were transfected with 100 ng/well of pMAXGFP (Lonza) using TransIT®-LT1 Transfection Reagent with a 2:1 reagent-to-DNA ratio according to the manufacturer’s instructions. Fluorescent images were taken 3 days post transfection using a Olympus IX71® inverted microscope. See more information on stem cell applications.

Data courtesy of
CDI logo


TransIT-LT1 Transfection Reagent HepG2 Toxicity Data

The TransIT®-LT1 Reagent Exhibits Higher Expression and Lower Cellular Toxicity Compared to Other Transfection Reagents. HepG2 cells were transfected with a luciferase expression plasmid using the designated reagents at the manufacturer’s recommended reagent-to-DNA ratio indicated beneath each bar. Transfections were performed in 96-well plates using 0.1 µg of plasmid DNA per well. Luciferase expression (bar graph) and lactate dehydrogenase (LDH) levels (line graph) were measured at 24 hours post-transfection. LDH levels are reported as % cytotoxicity compared to cells alone and were measured using a commercially available colorimetric assay; all values at or below zero are represented as zero on graph. Experiments were performed as per industry accepted testing protocols. FuGENE® is a registered trademark of Fugent LLC. Lipofectamine® is a trademark of Life Technologies Corporation.

TransIT-LT1 Transfection Reagent Competitor Summary Data

Comparable Luciferase Expression with the TransIT®-LT1 Reagent and FuGENE® 6 in Multiple Cell Types. The indicated cell lines were transfected in duplicate with 1 µg of a luciferase expression vector per well of a 12-well plate using either 3 µl of the TransIT®-LT1 or FuGENE® 6 Reagents according to industry accepted testing protocols. Cells were harvested 24 hours post-transfection and assayed for luciferase activity. FuGENE® is a registered trademark of Fugent LLC.



Storage Conditions
All Configurations: Store at 4°C

Product Guarantee
All Configurations: 1 year

Usage Statement
All Configurations: For Research Use Only.

Animal Origin Statement
All Configurations: This product contains raw materials that are derived from animals.

Technical Product Literature

Full Protocol
TransIT®-LT1 Full Transfection Protocol (PDF)

Additional Protocol
TransIT®-LT1 for iPSC Reverse Transfection (PDF)

Quick Reference Protocol
TransIT®-LT1 Quick Ref Protocol (PDF)

TransIT®-LT1 SDS (PDF)

Optimization Protocols
Optimization Protocol for DNA Transfection (PDF)

Video Protocol
Watch Video Protocol


Additional Resources

Why compromise your transfection results with toxicity?
Stem cell applications
Protocol: Reverse Transfection of Human Induced Pluripotent Stem (iPS) Cells with TransIT®-LT1 Transfection Reagent (PDF)


See the TransIT-LT1 FAQs

Using transfection reagents and enhancers from Mirus has given our platform a competitive advantage. Increasing efficiency and lowering costs for all of our porgrams.


Sally Mader, PhD
ZYZ Theraputics